SCHEMBL802849

SCHEMBL802849

Cc1ccccc1-c1cc2ccccc2c(Nc2nc[nH]n2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
BTK Q06187 2/20 0.36
TACR3 P29371 1/20 0.35
GSK3A P49840 1/20 0.35
GSK3B P49841 1/20 0.35
CYP1A2 P05177 7/20 0.35
CYP2C19 P33261 6/20 0.35
CYP3A4 P08684 5/20 0.35
CYP2D6 P10635 5/20 0.35
CLK4 Q9HAZ1 5/20 0.35
MAPK1 P28482 3/20 0.35
TSHR P16473 2/20 0.35
HPGD P15428 1/20 0.35
ADORA3 P0DMS8 4/20 0.35
IDO1 P14902 1/20 0.35
METAP2 P50579 1/20 0.35
ALOX15 P16050 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL802508 0.85 PDE4A (0.43) ALDH1A1NPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL786269 0.82 ACP1 (0.45) ALDH1A1CYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL801844 0.80 GSK3A (0.48) ALDH1A1NPC1RAB9ASMN1; SMN2TACR3
SCHEMBL802278 0.72 CCNA2 (0.40) ALDH1A1NPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL802841 0.70 CDK2 (0.41) ALDH1A1CYP1A2CYP2C19CYP2D6CLK4
SCHEMBL802281 0.69 CYP1A2 (0.47) ALDH1A1CYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL12620471 0.68 ACP1 (0.36) ALDH1A1CYP1A2CYP2C19CYP3A4CYP2D6
SCHEMBL9792794 0.68 NPY5R (0.55) ALDH1A1GSK3AGSK3BLMNAKDM4E
SCHEMBL801648 0.68 SYK (0.44) ALDH1A1CYP1A2CYP3A4CLK4ALOX15
SCHEMBL802343 0.68 AURKA (0.55) GSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed
US-7951820-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 ALDH1A1 4768/4885NPC1 2844/4885RAB9A 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.